CH4987655 / Roche - LARVOL DELTA

Functional Polymorphisms of the Arachidonic Acid Pathway Associate with Risks and Clinical Outcomes of Allergic Diseases. (PubMed, Int Arch Allergy Immunol) - "The present study identified multiple allergy-associated SNPs that modulate the transcript expressions of key genes in the AA pathway. The development of a "personalized medicine" approach with consideration of genetic influences on the AA pathway may hopefully result in efficacious strategies to manage and treat allergic diseases."

Clinical data • Journal • Allergic Rhinitis • Allergy • Asthma • Immunology • Inflammation • Pediatrics • Pulmonary Disease • Respiratory Diseases • MT-CO2 • PTGDR • PTGDR2

Integrated profiling uncovers prognostic, immunological, and pharmacogenomic features of ferroptosis in triple-negative breast cancer. (PubMed, Front Immunol) - "The high-risk group had a higher response to anti-PD-1 blockade or sunitinib, and the low-risk group had higher sensitivity to cisplatin. Two Cancer Therapeutics Response Portal (CTRP)-derived agents (SNX-2112 and brefeldin A) and PRISM-derived agents (MEK162, PD-0325901, PD-318088, Ro-4987655, and SAR131675) were predicted, which were intended for high-risk patients. Altogether, our findings unveil prognostic, immunological, and pharmacogenomic features of ferroptosis in TNBC, highlighting the potential clinical utility of ferroptosis in TNBC therapy."

Biomarker • IO biomarker • Journal • Breast Cancer • Immunology • Oncology • Solid Tumor • Triple Negative Breast Cancer

MEK 1/2 inhibitors in the treatment of gynecologic malignancies (Gynecol Oncol) - “This paper reviews the translational evidence in favor of MEK inhibitors in cancer, their role in gynecologic malignancies, and details regarding the status of the fourteen MEK inhibitors currently being clinically tested: trametinib, selumetinib, pimasertib, refametinib, PD-0325901, MEK162, TAK733, RO5126766, WX-554, RO4987655, cobimetinib, AZD8330, MSC2015103B, and ARRY-300.” 

Review • Oncology

A Dose-Escalating Study of RO4987655 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=145; Completed; Sponsor: Hoffmann-La Roche; Active, not recruiting -> Completed ; Trial primary completion date: Feb 2014 ->Dec 2014

Trial completion • Trial primary completion date • Biosimilar • Melanoma • Oncology

A dose-escalating study of RO4987655 in patients with advanced solid tumors (clinicaltrials.gov) - P1, N=80; Recruiting

Melanoma • Oncology

Phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumours (Clin Cancer Res) - P1, N=49; Study ID: BO21189; The pharmacokinetic profile of RO4987655 demonstrated dose-linearity & a half-life of ~4 hours; Of the pts evaluable for response, clinical benefit was seen in 21.1%, including two PR (one confirmed & one unconfirmed); 79.4% of pts demonstrated a reduction in fluorodeoxyglucose uptake by positron emission tomography between baseline & Day 15

P1 data • Oncology